The Europe Inflammatory Bowel Disease Treatment Market would witness market growth of 7.3% CAGR during the forecast period (2021-2027).
The main types of inflammatory disease are ulcerative colitis and Crohn’s disease. Patients suffering from Crohn’s disease may experience swelling and pain in the digestive tract. Also, patients can witness its effect on any part of the body from the mouth to the anus. It has a greater impact on the upper part of the large intestine and whole small intestine, majorly. In ulcerative colitis, patients witness swelling and sores (ulcers) in the large intestine (colon and rectum). Moreover, it causes intestinal inflammation that can be identified using a microscope.
The stressful & sedentary lifestyle and growing consumption of unhealthy drinks & food, leads to different digestive disorders and hence, boosting the demand for the market. Additionally, government and private companies are heavily investing in the healthcare sector which is estimated to escalate the growth of the market. Moreover, increasing research and development activities related to inflammatory bowel disease drugs will create new growth avenues for the inflammatory bowel disease treatment market in the forthcoming years. On the other hand, harmful effects like nausea, cramps, loss of appetite, and mild stomach pain, strict government regulations coupled with the efficacy and safety of the drug, and higher cost of drugs are the factors that would slow down the growth of the market in the coming years.
The inflammatory bowel disease treatment market is strongly growing in Europe. Europe comprises various well-established nations such as Spain, Norway, Germany, Italy, the UK, and France that are contributing to the growth of the inflammatory bowel disease treatment market. The increasing number of individuals engaged in smoking, evolving lifestyle, and rising prevalence of inflammatory bowel disease treatment are the factors supporting the growth of the market in this region.
Besides, the European Federation of Crohn's & Ulcerative Colitis Associations is the organization that continuously monitors inflammatory bowel disease patients in the region and is highly involved in the development of alternatives for inflammatory bowel disease treatment. Moreover, unhealthy eating and smoking practice, especially among youngsters has led to an increase in the prevalence of inflammatory bowel disease. Thus, these factors are anticipated to boost the demand and growth of the regional inflammatory bowel disease treatment market in the forthcoming period.
The Germany market dominated the Europe Aminosalicylates Inflammatory Bowel Disease Treatment Market by Country 2020, thereby, achieving a market value of $169.8 million by 2027. The UK market is exhibiting a CAGR of 8.8% during (2021 - 2027). Additionally, The France market is anticipated to witness a CAGR of 11.2% during (2021 - 2027).
Based on Type, the market is segmented into Crohn's Disease and Ulcerative Colitis. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. Based on Route of Administration, the market is segmented into Injectable and Oral. BBased on Drug Class, the market is segmented into TNF inhibitors, Anti-integrin, IL inhibitors, Corticosteroids, JAK inhibitors, Aminosalicylates and Others. ased on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global Inflammatory Bowel Disease Treatment Market Size will Hit $29.2 Billion by 2027, at a CAGR of 8.1%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Allergan PLC (AbbVie), Johnson & Johnson, Merck Group, Amgen, Inc., Eli Lilly and Company, Biogen, Inc., Pfizer, Inc., Novartis AG, Takeda Pharmaceutical Company Limited, and UCB S.A.
By Type
By Distribution Channel
By Route of Administration
By Drug Class
By Country
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 